Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044364 | 0.83 | ALDH1A1 (0.42) | LMNATSHRKDM4EALDH1A1POLB | |
| SCHEMBL14455151 | 0.82 | LMNA (0.60) | LMNATSHRALDH1A1POLBKMT2A | |
| SCHEMBL13227791 | 0.81 | TSHR (0.48) | LMNATSHRKDM4EALDH1A1KMT2A | |
| SCHEMBL1559633 | 0.80 | — | — | |
| SCHEMBL12421758 | 0.79 | ALDH1A1 (0.42) | LMNATSHRKDM4EALDH1A1HPGD | |
| SCHEMBL211904 | 0.78 | ALDH1A1 (0.56) | LMNATSHRKDM4EALDH1A1HPGD | |
| SCHEMBL23135308 | 0.77 | ALDH1A1 (0.41) | LMNATSHRKDM4EALDH1A1HPGD | |
| SCHEMBL2607883 | 0.77 | LMNA (0.54) | LMNATSHRKDM4EALDH1A1POLB | |
| SCHEMBL7996837 | 0.76 | ALDH1A1 (0.59) | LMNATSHRALDH1A1HPGDKMT2A | |
| SCHEMBL22224173 | 0.76 | ALDH1A1 (0.59) | LMNATSHRALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | TMSB4X, TMSB10, TAP1 | LMNA 4062/4885TSHR 2408/4885KDM4E 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.